Maria-Victoria Mateos - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Maria-Victoria Mateos's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Maria-Victoria Mateos
Verified
Editorial Board, Blood Cancer Journal
Beats
Mental health, Infectious Diseases , Digital Technologies, Bacteria, Vaccines , Innovation, Viruses , Global Health
Products or personal services
Content
By Maria-Victoria Mateos| OncLive Verified CommentaryVideoApril 9, 2025Author(s):María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes. "The next step is, of course, to move [cilta-cel] into the first line of therapy.
Dr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 Study of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
By Maria-Victoria Mateos| OncLive Verified CommentaryVideoApril 1, 2025Author(s):María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.
By Maria-Victoria Mateos| OncLive Verified CommentaryVideoApril 9, 2025Author(s):María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes. "The next step is, of course, to move [cilta-cel] into the first line of therapy.
Company Info
Blood Cancer Journal
Hoboken, New Jersey, United States
'+1 201-748-6000